HUTCHMED (China) Ltd (HKSE:00013)
HK$ 26.85 -0.35 (-1.29%) Market Cap: 23.27 Bil Enterprise Value: 17.96 Bil PE Ratio: 0 PB Ratio: 4.07 GF Score: 77/100

Half Year 2021 HUTCHMED (China) Ltd Earnings Call Transcript

Jul 28, 2021 / 12:00PM GMT
Release Date Price: HK$66 (+9.00%)
Operator

Ladies and gentlemen, welcome to this conference. I now hand over to Christian Hogg, CEO of HUTCHMED. Sir, please go ahead.

Christian Lawrence Hogg;China;Limited;Former CEO;Executive Director
HUTCHMED

()-&

Thank you very much, Greg. Welcome, everybody, to the first half results presentation for HUTCHMED for H1 2021. I'm joined on this call by my colleagues, Dr. Wei-Guo Su, our Chief Scientific Officer; Dr. Marek Kania, our Managing Director for HUTCHMED International, our Chief Medical Officer in the United States; Johnny Cheng, our Chief Financial Officer; and Mark Lee, our Senior Vice President Corporate Finance and Development.

So I'm looking forward to taking you through the presentation today. So if you could move to the next slide, please, Slide #3. The agenda today, what I'm going to do is I'll take you through this presentation, hopefully, in about 35 minutes. It will be relatively rapid fire, updating on everything. And then we'll open up for maybe half an hour of Q&A, at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot